<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82097">
  <stage>Registered</stage>
  <submitdate>17/06/2007</submitdate>
  <approvaldate>14/03/2008</approvaldate>
  <actrnumber>ACTRN12608000133336</actrnumber>
  <trial_identification>
    <studytitle>Effects of a Chinese herbal preparation containing Radix Polygoni Multiflori and Radix Salviae Miltiorrhizae on cardiovascular disease risk</studytitle>
    <scientifictitle>Effects of a Chinese herbal preparation containing Radix Polygoni Multiflori and Radix Salviae Miltiorrhizae on cardiovascular disease risk</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular risk</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with a Chinese medicine herbal preparation, the He Shou Wu Capsule (containing four Chinese herbs) in capsule form, 1 packet of capsules three times/day (oral administration) for 12 weeks.</interventions>
    <comparator>Matched placebo (polyethylene glycol 6000 [PEG 6000] plus caramel) in capsule form. Oral administration. One packet of capsules three times/day for 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Calculated cardiovascular risk using PROCAM algorithm</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adhesion molecule expression</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy individuals aged 18 years and over with a total plasma cholesterol of 5.0 mmol/L or above, triglyceride level of greater than 2 mmol/L or high density lipoprotein (HDL) cholesterol level of less than 1.0 mmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria included: plasma triglyceride levels over 10 mmol/L, established heart disease, other serious medical or psychological conditions, pregnancy, current use of vasoactive medications, warfarin, and postmenopausal hormone therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Study medications labelled sequentially and numerically. Computerised random number generated code used to determine study medication assignment (i.e herbal medicine or placebo). Study medications allocated to participants in order of enrolment into study.</concealment>
    <sequence>Computerised random number generator</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3004</postcode>
    <postcode>3181</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Monash Medical School
Alfred Lane
Prahran VIC 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australia-China Fund</fundingname>
      <fundingaddress>Commonwealth Dept of Education, Science and Training
Canberra ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Tianjin Tasly Pharmaceutical Co Ltd</fundingname>
      <fundingaddress>1 Liaohe East Rd and New Yibai St
Tianjin 300402</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This parallel double-blinded and randomised placebo controlled study examined effects of He Shou Wu Capsule (HSWC), a pharmaceutical preparation derived principally from the Chinese herbs Radix Polygoni Multiflori, Radix Salviae Miltiorrhizae, on a range of cardiovascular disease risk factors in subjects with mild to moderate hypercholesterolemia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash University Ethics Committee</ethicname>
      <ethicaddress>Department of Medicine
Monash University
Clayton Campus
Clayton VIC 3168</ethicaddress>
      <ethicapprovaldate>16/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Alfred Hospital
Commercial Rd
Prahran VIC 3181</ethicaddress>
      <ethicapprovaldate>6/01/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Paul Komesaroff</name>
      <address>Monash University
Department of Medicine
Alfred Hospital
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 99030622</phone>
      <fax />
      <email>paul.komesaroff@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Paul Komesaroff</name>
      <address>Monash University
Department of Medicine
Alfred Hospital
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 99030622</phone>
      <fax />
      <email>paul.komesaroff@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kylie O'Brien</name>
      <address>Faculty of Health, Engineering and Science
Victoria University
PO Box 14428
Melbourne VIC 8001</address>
      <phone>+61 3 99192792</phone>
      <fax />
      <email>kylie.obrien@vu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>